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SMN Dosage Analysis and Risk Assessment for Spinal
Muscular Atrophy
To the Editor:
Feldko¨tter et al. (2002) recently reported a new method
to determine, on the basis of real-time, quantitative PCR,
copy numbers of SMN1 (MIM 600354) and SMN2
(MIM 601627). Their method allows a greater degree of
automation and a faster turnaround time than do meth-
ods that have been described elsewhere (McAndrew et al.
1997; Chen et al. 1999; Wirth et al. 1999; Ge´rard et al.
2000; Scheffer et al. 2000; Ogino et al. 2001). Using their
new method, they demonstrated that the copy number of
SMN2—which is the centromeric homologue of SMN1,
the disease gene for spinal muscular atrophy (SMA [MIM
253300 for type I; MIM 253550 for type II; and MIM
253400 for type III])—influences the severity of SMA in
affected individuals with homozygous deletions of SMN1.
They found that, the greater the copy number of SMN2
was, the greater the likelihood was of a milder SMA type.
Because this correlation is not absolute, they used Bayes-
ian-type analyses to determine the posterior probabilities
of developing each SMA type, with both a homozygous
deletion of SMN1 and a given copy number of SMN2.
We discuss below several important ethical, prognostic,
and technical issues raised in their article.
In table 6, Feldko¨tter et al. report “Probabilities That
an Unaffected Who Has Been Tested after Birth and Has
Been Found to Carry a Homozygous Absence of SMN1
Will Develop Type I, II, or III SMA, on the Basis of
Number of SMN2 Copies.” SMA is usually a childhood-
onset disease, and testing of unaffected children is eth-
ically problematic. We agree with the American Society
of Human Genetics and the American College of Med-
ical Genetics that “Timely medical benefit to the child
should be the primary justification for genetic testing in
children and adolescents” (American Society of Human
Genetics Board of Directors and American College of
Medical Genetics Board of Directors 1995, p. 1233).
Since there are currently no effective treatments, pre-
symptomatic or otherwise, for SMA, the timely medical
benefit of the testing of unaffected children is unclear.
For the purpose of predicting SMA type from the
SMN2 copy number in unaffected children who lack
SMN1, Feldko¨tter et al. perform Bayesian-type anal-
yses by use of odds ratios, rather than conventional
conditional probabilities. For the prior probabilities,
they use the distribution of types of SMA among in-
dividuals affected with SMA: .51, for type I; .32, for
type II; and .17, for type III. Even if one were to test
unaffected children in this way, for this purpose, these
prior probabilities would not be the correct ones to use
for Bayesian or Bayesian-type analyses. If a child is
asymptomatic at age 10 mo, for example, he or she is
much less likely to have type I SMA than to have one
of the other types (Zerres and Rudnik-Scho¨neborn
1995). One would have to incorporate the conditional
probabilities of being asymptomatic at a particular age,
for the hypothesis of each SMA type.
The data on SMN2 copy number given by Feldko¨tter
et al. could be used in prenatal testing, to predict SMA
type. However, the prior probabilities that they use
would be applicable only if the family history of SMA
is of an unknown type. Although families with more
than one type of SMA have been described—and are
far from rare—knowing the type of SMA in an affected
family member increases the prior probability of that
type of SMA in a relative who is at risk of developing
SMA. If the type of SMA in that affected family mem-
ber is unknown, then the distribution of SMA types
among all individuals with SMA would be relevant to
the assignment of prior probabilities.
On the basis of all reported data, Feldko¨tter et al.
state that, because two SMN1 copies were found on 20/
834 (2.4%) healthy chromosomes, “4.8% of normal in-
dividuals would be misinterpreted as noncarriers on the
basis of the direct SMN1 test” (p. 365). Actually, these
data imply that ∼4.8% of noncarriers would have three
copies of SMN1 and that ∼2.4% of carriers with an
SMN1 deletion on one chromosome 5 would have two
SMN1 copies on the other chromosome 5. We have re-
ferred to the latter as the “ ” genotype (Chen et al.2 0
1999). Taking into account the ∼1.7% of carriers who
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have an intragenic mutation undetectable as an SMN1
exon 7 deletion, Feldko¨tter et al. state that this “reduces
the sensitivity of the test to 93.5% for a person from
the general population” (p. 365). Combining the ∼1.7%
of carriers who have an intragenic mutation with the
∼2.4% (i.e., ) of carriers who have0.024 # [1 0.017]
the genotype gives the overall sensitivity of SMN2 0
dosage analysis for the detection of SMA carriers in the
general population as ∼95.9%. If an affected family
member were known to have a homozygous deletion of
SMN1, then the sensitivity of SMN dosage analysis for
the detection of carriers among unaffected family mem-
bers would be ∼97.6% (i.e., ). This is0.959/[1 0.017]
because the probability of an intragenic-mutation carrier
in this family is greatly decreased relative to the prob-
ability of a carrier (Ogino et al., in press).2 0
Updating our combined data (McAndrew et al. 1997;
Ogino et al. 2002, in press) gives 23 of 590 normal chro-
mosomes 5 that have two copies of SMN1. Combining
these data with those of Feldko¨tter et al. gives a total of
37 of 1,120 (3.3%) normal chromosomes 5 that have
two copies of SMN1. We excluded other data in the lit-
erature (Wirth et al. 1999; Ge´rard et al. 2000; Scheffer
et al. 2000), for reasons described elsewhere (Ogino et
al., in press). On the basis of these numbers, ∼3.2% (i.e.,
) of carriers would have the ge-0.033 # [1–0.017] 2 0
notype. Therefore, the sensitivity of SMN dosage analysis
for the detection of carriers in the general population
would be ∼95.1%, and that for the detection of carriers
in a family with an affected individual lacking SMN1
would be ∼96.7% (i.e., ).0.951/[1 0.017]
Taking advantage of the single nucleotide differences
between SMN1 and SMN2 in both exon 7 and intron 7,
Feldko¨tter et al. used gene-specific primer pairs to amplify
only SMN1 or only SMN2. The primer pairs for each
gene were mismatched for the other gene at either the
final or the penultimate nucleotide from the 3′ end. These
mismatches corresponded to the sequence differences in
exon 7 (forward primers) and intron 7 (reverse primers).
Gene conversions between SMN1 and SMN2,which have
been reviewed elsewhere (Burghes 1997), could poten-
tially complicate this approach. If the SMN1 exon 7 se-
quence (C) were converted to the SMN2 exon 7 sequence
(T) but the SMN1 intron 7 sequence remained the same,
the converted gene would presumably function as an
SMN2 gene in vivo. This is because the CrT transition
in exon 7 of SMN2, although translationally silent, de-
creases the activity of an exonic splicing enhancer, so that
less full-length protein is expressed (Lorson et al. 1999;
Monani et al. 1999; Jong et al. 2000). By use of the gene-
specific primers given by Feldko¨tter et al., the converted
gene might have a different amplification efficiency from
that of the normal SMN1 or SMN2 gene. Primers that
are allele specific only for the functionally important poly-
morphism in exon 7 but not for the polymorphism in
intron 7 might alleviate this problem.
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Reply to Ogino and Wilson
To the Editor:
Drs. Ogino and Wilson (2002 [in this issue]) raised some
issues regarding our paper on quantitative testing of
SMN1 and SMN2 in spinal muscular atrophy (SMA)
(Feldko¨tter et al. 2002). First, they raised some ethical
issues regarding the testing of unaffected children for
SMA. We are also aware of the controversial aspects of
such testing and, in general, agree with Drs. Ogino and
Wilson: the identification, at birth, of homozygous ab-
sence of SMN1 in children, followed by the quantitative
analysis of SMN2, should be offered as a prognostic tool
only when a therapy for SMA is available. In this case,
a newborn screening (similar to that in phenylketonuria)
could—and possibly should—be considered. Since sev-
eral drugs that up-regulate full-length SMN2 have been
found (Andreassi et al. 2001; Chang et al. 2001) and
since the identification of many more is in progress, the
development of a therapy for SMA seems likely to be-
come a reality in the near future. Therefore, the devel-
opment of a highly sensitive and fast method to deter-
mine the number of SMN2 copies will be an essential
prerequisite before starting a therapy. Furthermore, the
identification, immediately after birth, of children who
carry homozygous absence of SMN1 will be equally es-
sential, to start the therapy before the motor neurons
are degenerated. On the basis of the number of SMN2
copies, the dosage and starting-point of a therapy may
significantly vary.
Since an efficient therapy has to be started early, we
calculated the posterior probability that a child with an
SMN1 deletion would develop type I, type II, or type III
SMA, under the assumption that the analysis is done
immediately after birth. As a consequence, we have used
a Bayesian-type analysis that is based on the odds ratios
and a priori probabilities as chosen.
We reevaluated the sensitivity calculations, and we
agree with Drs. Ogino and Wilson that the sensitivity
of the test, for the detection of an SMA carrier from the
general population without family history, is 95.9% (i.e.,
), since 2.4% of carriers have two1 [0.024 0.017]
SMN1 copies per chromosome and 1.7% carry intra-
genic SMN1 mutations. Therefore, there is a posterior
probability of ∼1:850 (i.e., ) that a[4.1/100] # [1/35]
person from the general population who carries two
SMN1 copies is an SMA carrier. The carrier frequency
of 1:35 is based on the results presented in our previous
article (Feldko¨tter et al. 2002). The sensitivity of the test
for the detection of an SMA carrier from a family with
an affected patient who carries a homozygous absence
of SMN1 is 97.6% (i.e., ).1 0.024
With reference to the primers designed to detect either
SMN1 or SMN2, the test is based on two nucleotide
differences in exon 7 and in intron 7 (position 100).
This implies that converted SMN genes may amplify
with a decreased efficiency. At this point, it is important
to mention that, in the large majority (42/44 [∼95%])
of converted SMN genes, the complete gene, except for
the region containing the nucleotide difference in exon
8, is converted (Hahnen et al. 1996). This means that,
for most converted SMN genes, the two primers that we
have applied lie in either SMN1 or SMN2 only and will
not hamper the efficiency of the PCR. Additionally, the
analysis of 20 patients with only homozygous absence
of SMN1 exon 7 showed identical number of SMN2
copies analyzed with both methods—multiplex com-
petitive PCR (Wirth et al. 1999) and LightCycler PCR
(Feldko¨tter et al. 2002). Nevertheless, the efficiency of
the PCR may be reduced for those rarely observed SMN
